A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
about
Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?An Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassNutritional modulation of endogenous glucagon-like peptide-1 secretion: a reviewDietary capsaicin and its anti-obesity potency: from mechanism to clinical implications.Medical Management of Diabesity: Do We Have Realistic Targets?Anti-obesogenic and antidiabetic effects of plants and mushrooms.Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-AnalysisExenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-DiabetesLimiting glucocorticoid secretion increases the anorexigenic property of Exendin-4Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainEffect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.An overview of new GLP-1 receptor agonists for type 2 diabetes.Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany.Albiglutide-induced pancreatitis.Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells.Monoacylglycerol signalling and ABHD6 in health and disease.Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.Calcium-dependent ultrasound stimulation of secretory events from pancreatic beta cells.Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.Gut hormone polyagonists for the treatment of type 2 diabetes.A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet.Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review.Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism.A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
P2860
Q26744254-42E26119-9560-429E-B87C-B1FB0A3DD734Q26749089-805A111F-169A-4BDE-86C7-A6045D627DEFQ28070256-CEEC88EA-1E5B-4126-A73E-20B425C15A6EQ30234738-1BB21EF5-4611-45F6-ABB8-DD7F1CB00245Q30238940-71B3BCDE-C9DA-4D3A-B28D-6ECFDD7C9364Q30241950-7AE8BB99-01E2-4E54-A2E5-04DF9334142AQ31140045-00EDD863-90BE-4753-B623-1E4BB343B099Q36072493-CCB78371-CFF2-484D-815A-BA8FFD9CABD4Q37040179-14838C60-9AAC-436C-BF44-8D5A03C6B2D6Q37501257-8EDDCDD6-5783-4B28-B4E0-E6E4F5370E1CQ37639302-16BA96BD-58E9-44DB-AFA0-8E574DCC6CDDQ37737468-85F703F1-B245-4CBE-A139-2BCF61E12C03Q38372172-BF2E9A81-DD26-4372-8F97-B573D99EE835Q38639922-7BD0A05E-56AB-44BB-A552-194C376B36A0Q38690867-C5D6633D-8A0E-427B-BEE1-1F228AE96B0EQ38765656-3C7349E8-8FD5-44FA-BAB4-C13EA2D8093EQ38922177-1337618E-0680-470C-94D4-FE9655CA7B13Q38937735-D27D19AA-35CA-4DC2-9897-C9B4F27F251BQ39290337-6C9E0677-3FAD-4BA7-80AC-D87699168B20Q39337620-5EC7957C-0E02-47AB-9980-3720A8586457Q39350860-EBF1240E-CB20-416A-AAD3-65DAB5D8B46AQ39413453-88AD3011-430C-43C6-9272-04A03E121943Q41086086-E24EC7BE-9E18-4499-B1EE-C8A4B9AF15FBQ42365383-328D4CC3-EFA1-4661-9F1A-50D12E850FB9Q42371337-7A81D3F7-4A59-4E46-AA36-3253774052CCQ44197738-91C0A729-FD85-436E-B803-2CB550C319CCQ46310918-B0872A0D-63D3-4D55-A543-3F82F8F79475Q47190800-AD38262D-20AC-4AC2-9989-62FDED706584Q47275144-EC94EC7E-90EB-4C71-97C5-0370242AE7DFQ48178209-E3AEDCBB-109F-4107-B917-4704ED3C1C69Q48221158-29A12C86-EBC2-4197-970B-62F22AD77BFCQ48274676-D86A952F-E217-4781-B704-58060BF212D0Q49218095-7198732C-B7BF-4108-931D-B5DA4A4E4B2DQ51244521-DF599308-1641-4F87-A641-7B1D05376288Q51259492-4B61F054-CB1B-4CB0-87CA-4941EAB63B88Q51289884-4936DC3B-C092-4723-9277-7CF740E717A6Q52343188-8C19E482-1150-4D3C-ABE1-15218D8CEB95Q52371944-E7731715-F4B8-4081-A8C5-70FAF4B59159Q52575496-C40E35E9-7756-4565-A880-05F7E169E68DQ52662396-570AE218-B8B6-4808-92F5-0A25BE590131
P2860
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@ast
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@en
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@nl
type
label
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@ast
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@en
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@nl
prefLabel
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@ast
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@en
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@nl
P2860
P3181
P356
P1433
P1476
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
@en
P2093
Lalita Prasad-Reddy
P2860
P304
P3181
P356
10.7573/DIC.212283
P407
P50
P577
2015-07-09T00:00:00Z